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Abstract
Designer proteins deprived of its IgE-binding reactivity are being sought as a regimen for allergen-specific immunotherapy.
Although shrimp tropomyosin (Met e 1) has long been identified as the major shellfish allergen, no immunotherapy is
currently available. In this study, we aim at identifying the Met e 1 IgE epitopes for construction of hypoallergens and to
determine the IgE inhibitory capacity of the hypoallergens. IgE-binding epitopes were defined by three online
computational models, ELISA and dot-blot using sera from shrimp allergy patients. Based on the epitope data, two
hypoallergenic derivatives were constructed by site-directed mutagenesis (MEM49) and epitope deletion (MED171). Nine
regions on Met e 1 were defined as the major IgE-binding epitopes. Both hypoallergens MEM49 and MED171 showed
marked reduction in their in vitro reactivity towards IgE from shrimp allergy patients and Met e 1-sensitized mice, as well as
considerable decrease in induction of mast cell degranulation as demonstrated in passive cutaneous anaphylaxis assay.
Both hypoallergens were able to induce Met e 1-recognizing IgG antibodies in mice, specifically IgG2a antibodies, that
strongly inhibited IgE from shrimp allergy subjects and Met e 1-sensitized mice from binding to Met e 1. These results
indicate that the two designer hypoallergenic molecules MEM49 and MED171 exhibit desirable preclinical characteristics,
including marked reduction in IgE reactivity and allergenicity, as well as ability to induce blocking IgG antibodies. This
approach therefore offers promises for development of immunotherapeutic regimen for shrimp tropomyosin allergy.
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Introduction
Food allergy is a type 1 hypersensitivity disorder that affects up
to 10% of the general population [1] and frequently lead to
anaphylaxis. Food-related acute allergic reactions account for up
to 49% of all anaphylaxis-related emergency department (ED)
visits [2–4] and for patients discharged from ED, 54% filled
epinephrine autoinjection prescription within one year [5]. Among
all food allergies, shellfish allergy is one of the most common types
with a prevalence of 0.6% in the world population [6], and is
particularly common in Asian countries [7]. Shellfish is also
considered as one of the four most common food, which could
provoke anaphylaxis [8]. With an emerging trend in both shellfish
production and consumption, the increase in the prevalence of
shellfish allergy is predictable [9]. Improved clinical management
of this disorder is therefore needed, and comprehensive studies of
the molecular characteristics of shellfish allergens and therapeutic
regimens are eminent.
At the molecular level, the muscle protein tropomyosin was
identified as the major shrimp ingestion-related allergen in
Metapenaeus and Penaeus spp [10–12]. Biochemically, tropomy-
osin is a coiled-coiled secondary structure protein of 34–38 kDa
and functions in contractile activities of muscle cells [13]. While
shrimp allergy has long been a model for studying shellfish allergy,
our laboratory has cloned and expressed tropomyosin from
Metapenaeus ensis (Met e 1), which exhibits specific serological
IgE reactivity with serum samples from shrimp allergy patients
[11]. This study has facilitated the subsequent identification of
tropomyosin as an allergen common in crustaceans and mollusks
[14–18]. Greatly attributed to the high amino acid sequence
homology among the crustaceans and mollusks tropomyosins
(93.8% and 77.2%, respectively), as well as a 61.4% sequence
homology between the arthropods and mollusks tropomyosins, this
protein is believed to be the major cross-reactive shellfish pan-
allergen [13,19]. Specifically, there are more than 99% sequence
homology between the two most common reference shrimp
allergens Met e 1 and the tropomyosin from Penaeus aztecus
PLOS ONE | www.plosone.org 1 November 2014 | Volume 9 | Issue 11 | e111649
(Pen a 1) [12]. Met e 1 and Pen a 1 are therefore ideal model
allergens, to be engineered for shrimp allergy immunotherapy
studies but also possibly at other tropomyosin-induced shellfish
allergies.
Although food avoidance and epinephrine injection are
currently the first-line treatments in patients with anaphylaxis,
allergen-specific immunotherapy (SIT) is the major strategy for
clinical management of allergy as it has the capacity to modify the
course of the disease. However, conventional modalities for SIT
using native allergens are constrained due to the potential risk of
allergic side-effects during treatment. In this context, hypoallergen
with low/no IgE reactivity is desirable for SIT. Notably, the
nature of allergenic epitopes and hypoallergens might greatly
affect the SIT outcome such as the induction and generation of
blocking antibodies, shifting of the Th1/Th2 paradigm and
induction of peripheral tolerance by recruitment of regulatory T
cells [20–25]. Molecular characterization of allergens, exemplified
by the identification of IgE-binding epitopes, is thus imperative for
the design of safer immunotherapy regimens [26]. Ayuso et al.
have applied the concept of a hypoallergenic mutant by
introducing 12 point mutations into the eight IgE-binding epitopes
[27] within the five allergenic regions of Pen a 1 [28]. Although
this mutant showed a reduction of allergenic potency of 90–98%
in humanized rat basophilic leukemia (RBL) release assay,
maximal releases were similar between the mutant and wild-type
Pen a 1. This result suggests that other significant allergenic
epitopes may exist in addition to the eight allergenic sites reported,
thus additional approaches are necessary to construct a hypoaller-
gen of shellfish tropomyosin.
To circumvent this issue, we have chosen a two-pronged
approach in designing shrimp tropomyosin hypoallergens. In this
study, the first objective is to define the major IgE-binding epitopes
of Metapenaeus tropomyosin Met e 1. The second objective of this
study is to construct hypoallergenic derivatives of Met e 1 by
introducing point mutations within the IgE-binding epitopes
identified, or by deleting these epitopes. The IgE reactivity,
allergenicity, immunogenicity and the inhibitory potential of the
hypoallergen-induced antibodies towards IgE antibodies of sub-
jects allergic to shrimp and Met e 1-sensitized mice [29] are
characterized and compared to the wild type allergen Met e 1.
Herein, we specifically used serum samples from children and
adolescents allergic to shrimp in mapping the IgE-binding
epitopes. Previous study reported greater epitope diversity among
children allergic to shrimp than adult patients [30] and outgrown
of shellfish allergy is rarely reported [31,32]. We therefore believe
that the use of pediatric serum samples could resolve an epitope
profile of Met e 1 that is comprehensive, clinically relevant and
common among shrimp allergy patients in any age group. The
hypoallergens constructed based on this epitope profile should also
be applicable in immunotherapy targeting at both pediatric and
adult patients.
Materials and Methods
Serum samples
Serum samples were obtained from 12 subjects (aged 3–17
years) with confirmed clinical history of allergic responses to
shrimp and positive skin prick test (Table S1). Specific IgE
reactivities to purified recombinant shrimp tropomyosin Pen a 1
and Met e 1 were characterized by ImmunoCAP and ELISA,
respectively. None of the recruited subjects have other allergies.
Serum samples (n = 8) obtained from healthy, non-atopic volun-
teers without Met e 1-specific IgE were used as a negative control.
Ethics statement
A written consent was obtained from the parents of the children
enrolled in the study (Institutional Review Board of the University
of Hong Kong/Hospital Authority Hong Kong West Cluster, Ref.
No. UW10-115). The use and storage of human sera were
approved by the Joint Chinese University of Hong Kong - New
Territories East Cluster Clinical Research Ethics Committee with
a written informed consent (CREC Ref. No. CRE-2010-514). All
animal protocols were approved by the Animal Experimentation
Ethics Committee, The Chinese University of Hong Kong (ref
No. 11/006/GRF and 463911), in accordance with the Depart-
ment of Health (Hong Kong) guidelines in Care and Use of
Animals. All experiments were performed under licenses granted
from the Government of Hong Kong Special Administrative
Region.
Identification of allergenic epitopes
There were three independent methods used to predict the
immunodominant allergenic epitopes including 1) computational
prediction of IgE binding epitopes, 2) ELISA against overlapping
peptides that span the entire Met e 1 sequence, and 3) dot-
immunoblotting of overlapping peptides against the entire Met e 1
sequence. 18 overlapping peptides spanning the full-length (274
amino-acids) Met e 1 were commercially synthesized (GenScript).
Each peptide had 20 amino acids (except for peptide 18 that
contains 19 amino acids) with five amino acids overlapping with
the adjacent peptides at the N-terminus. Individual peptides were
dissolved in distilled water, aliquoted and stored at 220uC until
required.
1) Three computational models from the Immune Epitope
Database (IEDB) Analysis Resource were employed to predict
the major linear IgE-binding epitopes of Met e 1, including
Bepipred Antibody Epitope Prediction, Kolaskar & Tongaon-
kar Antigenicity model and Emini Surface Accessibility
Prediction. Bepipred Antibody Epitope Prediction predicts
the location of IgE-binding epitopes based on the hidden
Markov model and propensity scale method [33]. The
Kolaskar & Tongaonkar Antigenicity model is based on the
physiochemical properties of amino acid residues [34]. Emini
Surface Accessibility Prediction is based on the calculation of
the surface accessibility scale [35].
2) For peptide ELISA, 3 mg of each peptide were coated on 96-
well plates (Nunc, maxisorp) in 0.05 M carbonate buffer
overnight. After blocking with 1% BSA/PBS for 1.5 h, the
plates were incubated with individual serum samples (150
dilution) at room temperature for 2 h. Thereafter, the plates
were incubated with biotinylated goat anti-human IgE
(Vector) in 11000 dilution for 45 min followed by incubation
with Avidin D, Peroxidase labeled antibody (Vector) in 11000
dilution for 30 min. The plates were then developed with
TMB substrate reagent set (BD Biosciences) for 15 min and
the reaction was terminated by 2 N H2SO4. Absorbance was
measured at 450 nm using an ELISA plate reader (Bio-Rad).
All absorbance values were background-corrected, in which
the background absorbance was the OD value of Met e 1-
coated wells incubated with secondary and tertiary antibodies
only. All the above procedures were performed at room
temperature. The plates were washed with PBS/0.5% Tween-
20 (PBST) three times and PBS once between each step and
all dilutions were made in 1% BSA/PBS.
3) For dot-immunoblotting, 3 mg of each peptide (3 mL) were
spotted onto a 0.2 mm nitrocellulose membrane (Bio-Rad).
The membrane was allowed to air-dry and thereafter fixed
Hypoallergens of Shrimp Tropomyosin Met e 1
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with 2.5% glutaraldehyde/PBS for 10 min [36]. The
membrane was incubated with diluted serum (150 dilution)
overnight at 4uC after a 2-h blocking in 3% skim milk/TBS.
The membrane was incubated with mouse monoclonal anti-
human IgE-alkaline phosphatase antibody (Sigma Aldrich) at
12000 dilution for 1 h at room temperature followed by signal
development with NBT/BCIP (Roche). All dilutions were
made with 3% skim milk/TBS and all washing steps were
performed with TBST) once and TBS three times with
shaking.
Design of hypoallergenic shrimp tropomyosins
With the high structural flexibility and spontaneous unfolding
property of tropomyosin [37], we believe that the possibility of
having only one single amino acid per epitope that is crucial for
IgE binding is unlikely. Restricted homologous substitution may
not be sufficient to result in tropomyosin variants with greatly
reduced IgE reactivity. Therefore, the amino acid sequence of Met
e 1 was compared to the non-allergenic fish tropomyosins of four
species Salmo salar (Atlantic salmon; GenBank accession number
NP_001117128.1), Epinephelus coioides (orange-spotted grouper;
ADG29138.1), Siniperca chuatsi (Mandarin fish; AEK21799.1)
and Thunnus thynnus (Atlantic bluefin tuna; BAD01050.1) (Fig.
S1). All nine identified IgE-binding regions in Met e 1 were
converted into the homologous sequence of fish tropomyosins and
49 point mutations in total were introduced to construct the
mutation mutant MEM49 (Fig. 1A & B). To construct the deletion
mutant, all nine IgE-binding epitopes were deleted (Fig. 1B). This
mutant, named MED171, contained only 171 amino acid
residues. The amino acid sequences of MEM49 and MED171
were reverse translated using MEGA 5.0 and the encoding
sequences of the two mutants were synthesized commercially by
GenScript. Synthetic genes of each of the mutants were cloned
into pET30(a)+ (Novagen) expression vector via EcoRV and
HindIII restriction sites. The sequences and reading frame of
MEM49 and MED171 in the plasmid were confirmed by
dideoxynucleotide sequencing.
Preparation of recombinant wild type and mutant shrimp
tropomyosin
cDNA coding for the full length shrimp tropomyosin Met e 1
and the encoding sequences of MEM49 and MED171 were
cloned into His-tag expression vector pET30(a)+ (Novagen) and
expressed in Escherichia coli BL21 (DE3) (Invitrogen) by culturing
in MagicMedia (Invitrogen) at 37uC overnight. His-tagged
recombinant Met e 1 (rMet e 1), MEM49 and MED171 were
purified using the HisPur Cobalt Spin Column (Thermo Scientific)
according to the manufacturer’s instructions. Protein concentra-
tion was determined by BCA assay (Sigma Aldrich) while the
purity was determined by Sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) and Coomassie blue staining.
Mice sensitization and immunization
3–4 weeks old female Balb/c mice were acquired from the
Laboratory Animal Services Centre, The Chinese University of
Hong Kong. All animals were maintained on a shrimp-free diet
and housed in pathogen-free conditions. To induce Met e 1
hypersensitivity in mice, sensitization was performed as described
previously by intragastric administration of 0.1 mg of recombinant
tropomyosin plus cholera toxin on days 0, 12, 19 and 26 and
challenged on day 33 [29]. Mice fed with phosphate-buffered
saline plus cholera toxin were included as controls. Blood samples
were collected 4 h after the challenge for antibody analysis.
For immunization experiments, 5–6 weeks old female Balb/c
mice were intraperitoneally immunized three times on days 0, 7
and 14 with 0.1 mg purified rMet e 1, MEM49 or MED171
adsorbed to 1 mg Al(OH)3. Blood was collected 4 h after the last
injection for the determination of antibody levels.
Direct ELISA
To examine the IgE reactivity to rMet e 1, MEM49 or
MED171, 96-well ELISA plates were coated with 5 mg/mL of
either rMet e 1, MEM49 or MED171 in 0.05 M carbonate buffer
overnight at 4uC, blocked with 1% BSA/PBS for 2 h and
incubated with serum samples from shrimp allergy subjects or Met
e 1-sensitized mice (110 dilution) overnight at 4uC. After washing,
plates were incubated with biotinylated anti-human (Vector) or
anti-mouse IgE antibodies (BD Pharmigen) and Avidin D,
Peroxidase labeled antibody (Vector), each at 11000 dilution at
room temperature for 1 h and 30 min, respectively. The plates
were then developed with TMB substrate reagent set (BD
Biosciences) for 15 min and the reaction was terminated by 2 N
H2SO4.
To determine the reactivity of IgG and IgG2a antibodies raised
in rMet e 1, MEM49 and MED171 immunized mice, sera in serial
dilutions (1400 to 125600) were incubated in the rMet e 1,
MEM49 or MED171 coated plates (5 mg/mL) for 2 h at room
temperature. The plates were then incubated with goat anti-mouse
IgG or anti-mouse IgG2a (Southern Biotech) in 12000 dilution for
45 min followed by incubation with Avidin D, Peroxidase labeled
antibody (Vector) in 11000 dilution for 30 min. The plates were
then developed with TMB substrate reagent set (BD Biosciences)
for 5 min and the reaction was terminated by 2 N H2SO4.
Passive cutaneous anaphylaxis
Passive cutaneous anaphylaxis was performed to determine the
in vivo allergenicity of MEM49 and MED171. Backs of naı¨ve
Balb/c mice were shaved, followed by intradermal injection of
Met e 1-specific IgE-containing sera (undiluted sera in a total
volume of 100 mL) under isoflurane narcosis. Two hours later,
mice were injected intravenously with a mixture of 100 mL of
0.5% Evan’s blue dye (Sigma Aldrich) and 0.1 mg rMet e 1,
MEM49 or MED171. Thirty minutes after dye-rMet e 1
administration, mice were sacrificed by cervical dislocation and
skins of their backs were immediately inverted for the measure-
ment of blue region diameters.
Competitive inhibition ELISA
Competitive inhibition ELISA was performed to evaluate the
blocking capacity of hypoallergen-induced blocking antibodies.
Briefly, rMet e 1 was used to coat 96-well plates (5 mg/mL)
overnight at 4uC and blocked with 1% BSA/PBS for 2 h. Plates
were then washed and blocked with 100 mL of 110 diluted sera
from mice immunized MEM49, or MED171 overnight at 4uC.
Thereafter, 100 mL of sera from shrimp allergy patients or Met e
1-sensitized mice at a predetermined dilution (110–120 dilution)
were added and incubated at room temperature for 2 h. The wells
were then washed and followed by the addition of biotinylated
anti-human or anti-mouse IgE antibodies, HRP-Avidin D and
developed as described above. The blocking ability of the induced
IgG antibodies was determined using the equation [(ODno inhibitor–
ODinhibitor)/ODno inhibitor]6100% and expressed as percentage
inhibition.
Hypoallergens of Shrimp Tropomyosin Met e 1
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Statistical analysis
Data were presented as mean 6 SEM. The statistical
comparison was determined by one-way analysis of variance
(ANOVA) followed by the Student-Newman-Keuls test using
SigmaStat 3.1. The difference was considered statistically signif-
icant at p,0.05.
Results
IgE-binding epitopes of Met e 1 and hypoallergen design
By ELISA, sera from patients with shrimp allergy (n = 12) had
significantly higher IgE reactivity against five peptides (P3, P5,
P10, P13 and P16) when compared with other peptides (p,0.05)
(Fig. 2A). None of the sera from control subjects (n = 8) showed
IgE-binding activity towards these or other peptides (data not
shown).
Allergenic regions on Met e 1 were also defined based on the
intensity of peptide spots and the frequency of recognition in dot-
immunoblotting (Fig. 2B). A peptide with .50% recognition (6
out of 12 patients) or an epitope score (calculated by the
summation of the IgE reactivity score (strong reactivity: 3; median:
2; low: 1)) higher than the mean intensity score (8.83, calculated by
adding all epitope scores and dividing by 18 peptides) was defined
as a major IgE-binding epitope. Based on these criteria, eight
peptides (P1, P3, P10, P11, P15, P16, P17 and P18) were identified
as the major Met e 1-specific IgE-binding sequences. The
discrepancy in epitopes determined by ELISA and dot-immuno-
blotting (Fig. 2C) was apparently due to assay sensitivity and
peptide presentation on different materials in the two assays.
Three online immunoinformatics models were applied to define
the IgE epitopes. (Fig. 2C & Fig. S2). Seven epitopes, with six to 16
amino acid residues in length, were identified using Emini Surface
Accessibility Prediction based on the surface probability score (Fig.
S2A). Ten allergenic regions, between six to 19 amino acid
residues in length, were defined under the Kolaskar & Tongaonkar
Antigenicity model based on the antigenic propensity score (Fig.
S2B). Using Bepipred Antibody Epitope Prediction, 15 regions
from one to 28 amino acid residues in length were recognized as
IgE-binding epitopes (Fig. S2C). In comparing the predictions by
these three models, Emini Surface Accessibility Prediction and
Bepipred Antibody Epitope Prediction yielded very similar epitope
results (.85% similarity, calculated as the degree of overlapping
amino acid residues), while the prediction by Kolaskar &
Tongaonkar Antigenicity deviated from those of the other two
models. Only six regions resulted in consensus between Emini
Surface Accessibility Prediction and Kolaskar & Tongaonkar
Antigenicity, but with a low degree of overlap ranging between
14% and 37%.
Data obtained by ELISA and dot-immunoblotting, as well as
from the three predictions models, were combined and equally
weighted for defining the major IgE-binding epitopes (Fig. 2C).
Logically, sequences that are determined as IgE reactive both
experimentally and by modeling studies are more likely to
represent IgE-binding epitopes in the native protein. Therefore,
only regions that were suggested as IgE reactive by at least one of
the experimental assays, and at least two other of the above assays
or models, were considered as major epitopes [38]. Altogether,
nine major IgE-binding epitopes of Met e 1 ranging from five to
twenty-one amino acid residues in length were identified, namely
Figure 1. Design of two hypoallergenic mutants. MEM49 was constructed by substitution of 49 different amino acid residues within the nine
Met e 1 epitopes to the homologous fish tropomyosin sequence. MED171 was constructed by deletion of epitopes E1 to E9 of Met e1. (A) Location of
the IgE-binding epitopes in tropomyosin. The IgE epitopes designated as E1–E9 are shown in boxes and the location of the 49 amino acid residues in
Met e 1 that are converted in MEM49 are also shown as one letter amino acid code. (B) Schematic representation of Met e 1, MEM49 and MED171.
Epitopes E1 to E9 in Met e 1 are represented as black boxes and the number of amino acids in each epitope is indicated. Amino acid residue changes
in MEM49 are shown as *. MED171 is a truncated peptide with the epitopes E1–E9 deleted. (C) SDS-PAGE of Met e 1, MEM49 and MED171 after
Coomassie Blue staining. Note the 35 kDa molecular weight of Met e 1 and MEM49 and the expected smaller size of MED171 compared to Met e 1.
doi:10.1371/journal.pone.0111649.g001
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E1–E9, with positions at Met e 125–30, Met e 143–60, Met e 187–103,
Met e 1146–154 Met e 1161–165, Met e 1191–211, Met e 1236–241, Met
e 1247–255 and Met e 1269–281, respectively (Fig. 1A). Based on
these epitopes, we constructed two tropomyosin mutants, by site-
directed mutagenesis (MEM49) and epitope deletion (MED171).
The locations of the IgE epitopes and their corresponding amino
acid changes in mutants MEM49 and MED171 are shown in
Fig. 1A and B. Approximately 4 mg of purified soluble recombi-
nant proteins of MEM49 and MED171 could be obtained from 1
liter of E.coli culture. SDS-PAGE analysis of purified recombinant
proteins of the mutation mutant MEM49 and the deletion mutant
MED171 showed a 35-kDa MEM49 band and a 27-kDa
MED171 band, compared to a 35 kDa rMet e 1 band (Fig. 1C).
Immunoreactivity of tropomyosin mutants
Sera from 8/8 shrimp allergy patients and Met e 1-sensitized
mice showed a marked decrease in IgE reactivity to MEM49 and
MED171 (Fig. 3). Reactivity of MEM49 and MED171 towards
patient IgE decreased by an average of 71.4% and 77.4% relative
to Met e 1, respectively (Fig. 3A & B), while that to mouse IgE
decreased by an average of 90.5% and 97.6%, respectively
(Fig. 3C & D). Notably, the IgE-binding reactivity of MED171
was significantly lower than that of MEM49 (p,0.05) when tested
with mouse sera. In addition to in vitro reduction in IgE reactivity,
both MEM49 and MED171 did not trigger mast cell degranu-
lation in passive cutaneous anaphylaxis assays. In contrast to a .
2.5 cm blue region induced by intradermal injection of Met e 1-
specific IgE and intravenous injection of Met e 1 with Evan’s blue
dye, no Evan’s blue dye extravasation could be induced by
intravenous injection of either hypoallergens (Fig. 3E). More
Figure 2. Determination of Met e 1 IgE-binding epitopes. Epitopes were determined by ELISA, dot-immunoblotting and three prediction
models Emini Surface Accessibility Prediction Kolaskar & Tongaonkar Antigenicity model and Bepipred Antibody Epitope Prediction. (A) Histogram of
the IgE binding reactivity against the Met e 1 peptides as determined by ELISA. (B) Histogram of IgE binding reactivity against the Met e1 peptides as
determined by dot-immunoblotting. (C) Alignment of Met e 1 IgE-binding epitope sequences as determined by ELISA, dot-immunoblotting and each
of the three prediction models.
doi:10.1371/journal.pone.0111649.g002
Hypoallergens of Shrimp Tropomyosin Met e 1
PLOS ONE | www.plosone.org 5 November 2014 | Volume 9 | Issue 11 | e111649
importantly, none of the MEM49- or MED171-immunized mice
produced Met e 1-recognizing IgE antibodies (OD 0.07160.001
and 0.09260.003, respectively) and hypoallergen-specific IgE
antibodies, comparing to an IgE level of OD 0.40560.056 upon
Met e 1 immunization (Table 1). These clearly demonstrated that
both MEM49 and MED171 had marked reduction in their
in vivo allergenicity.
Hypoallergen-immunized mice produced Met e 1-
specific IgG antibodies and inhibited IgE binding to Met
e 1
Mice immunized with either rMet e 1, MEM49 or MED171
produced robust IgG antibodies that recognized rMet e 1 with OD
1.77860.037, 0.57160.082 and 1.08960.085, respectively (Ta-
ble 1). Moreover, IgG antibodies induced by MED171 exhibited
better rMet e 1 recognition when compared to those induced by
MEM49 at all tested dilutions (Fig. 4A). It is noteworthy that only
the hypoallergens MEM49 and MED171, but not Met e 1, could
induce the production of Met e 1-specific IgG2a antibodies
(Fig. 4B). We further examined if the sera IgG antibodies from
hypoallergen-immunized mice were able to block Met e 1-specific
IgE from binding to rMet e 1 by competitive inhibition ELISA.
Serological IgG from MEM49 and MED171 were able to inhibit
46.263.41% and 45.963.54% of IgE from shrimp allergy patients
from binding to Met e 1, respectively (Fig. 4C). MEM49- and
MED171-IgG could better inhibit mouse IgE binding to Met e 1
with average of 82.563.24% and 87.662.84%, respectively
(Fig. 4D).
Discussion
Knowledge of the IgE-binding epitopes of allergens is funda-
mental for designing hypoallergenic derivatives, which are
regarded as one of the best candidates applicable in SIT.
Successful SIT using hypoallergens has been well demonstrated
in mouse models of respiratory allergies [39–42] as well as in
clinical trials on birch pollen allergy patients [43–45]. The fish
parvalbumin mutant Mut-CD/EF that displays a 95% reduction
in IgE reactivity and ability to induce blocking IgG antibodies
might represent the only best-known hypoallergen among all the
most common food allergens [46]. Meanwhile, hypoallergens of
the major shellfish allergen tropomyosin that could be translated
into specific immunotherapy are unavailable.
Although several shrimp allergens including arginine kinase
[47,48], sacroplasmic calcium-binding protein [49,50], myosin
light chain [51,52] and troponin C [51] have been identified and
registered by the IUIS-allergen database, tropomyosin is reactive
to .80% patients allergic to shrimp and is regarded as the major
shrimp and shellfish cross-reactive allergen [10,11]. Herein, we
have defined the IgE-binding epitopes of the shrimp tropomyosin
Met e 1 by ELISA, dot-immunoblotting and three online models
as prediction tool represents an emerging strategy in epitope
mapping studies among food and drug allergies [38,53,54]. Using
this combination, we aimed to achieve higher accuracy, including
a lower chance of missing important epitopes, more complete
recovery and a higher resolution of epitopes. Using this approach,
nine major IgE-binding Met e 1 epitopes were identified. These
epitopes range from five to twenty one amino acid residues in
length, with some of these allergenic regions longer than the IgE-
binding epitopes of other allergens [53,55–57]. This variation may
be due to the relatively simple coiled-coiled secondary structure of
tropomyosin and/or the high flexibility of this molecule [37],
possibly resulting in the higher proportion of surface-exposing IgE-
binding sequences. The discovery that six IgE-binding epitopes
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identified in our work overlap with those previously reported for
Pen a 1 [27,28] is not surprising because the two proteins only
have one amino acid difference at residue 69. The three Met e 1
IgE epitopes (E1, E5 and E7) newly identified in this study
(Fig. 2A) may partly account for the limited success of a Pen a 1
hypoallergen in reducing allergenicity to shrimp tropomyosin [27].
Incidentally, serum samples from adults were used in the Pen a 1
study while serum samples from children and adolescents were
used in determining the IgE-binding epitopes of Met e 1. The
presumed greater epitope diversity in children with shrimp allergy
than adults [30] may account for the additional epitopes revealed
in the present study. Interestingly, some of the Met e 1 epitopes
predicted by Bepipred Antibody Epitope Prediction are only one
to five amino acid residues apart. Although this model was
designed for continuous B cell epitope prediction, a recent study
suggests that the results are similar to the predicted discontinuous
B cell epitopes [58]. Hence, the epitopes predicted by this model
may possibly represent the discontinuous epitopes of Met e 1,
although more sophisticated experiments such as crystal structure
resolution of allergen/IgE complex could be conducted to confirm
the identity of the discontinuous epitopes of Met e 1. Nevertheless,
the identification of previously unidentified IgE-binding epitopes
in our study as compared to the study on Pen a 1 may be partly
explained by the characterization of both linear and discontinuous
IgE-binding epitopes here.
In the immunotherapy of allergy, a major goal is to reduce IgE-
mediated side-effects during the course of immunotherapy. The
two major strategies to reduce IgE reactivity include mutating the
amino acid residues involved in IgE-binding, and disrupting the
three-dimensional structure of the allergen [59]. Based on our IgE-
epitope data, we constructed two hypoallergenic derivatives of Met
e 1.
First, hypoallergen MEM49 was constructed by replacing 49
amino acid residues within the nine Met e 1 IgE-binding epitopes
with the homologous tropomyosin sequences of fish. Tropomyosin
sequences of more than ten fish species are available on GenBank.
Herein, we have chosen tropomyosin sequences from four
common edible fish species, Salmo salar, Epinephelus coioides,
Siniperca chuatsi and Thunnus thynnus for comparison. To our
knowledge, these fish tropomyosins have not been documented as
ingestion-related allergens (however, see Liu et al. which shows
that tilapia tropomyosin may be related to autoimmune diseases
[60]) and are thus valid candidates for such a homologous
conversion. The advantage of homologous substitution is that
MEM49 would retain its natural conformation and thereby
ensuring a strong allergen-specific IgG response [61]. On the other
Figure 3. In vitro and in vivo IgE reactivity and allergenicity of the hypoallergens. Reactivity of (A) MEM49 and (B) MED171 to IgE from
shrimp allergy patients (n = 8) and reactivity of (C) MEM49 and (D) MED171 to IgE of Met e 1-sensitized mice (n = 8) in ELISA. (E) In vivo IgE reactivity
and allergenicity of Met e 1, MEM49 and MED171 as determined by PCA assay. Note that the in vitro and in vivo IgE reactivity and allergenicity of
MEM49 and MED171 are significantly lower than those of Met e 1, as shown by the significantly lower absorbance value at 450 nm and absence of
Evan’s blue dye extravasation.
doi:10.1371/journal.pone.0111649.g003
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hand, we believe that with the high structural flexibility of
tropomyosin and its spontaneous unfolding property [37], the
possibility of having only one single critical amino acid per epitope
that is responsible for IgE binding is unlikely. Therefore, restricted
homologous substitution may not be sufficient to significantly
reduce the IgE-binding reactivity of the variant. Hence, all the
identified IgE-binding regions in Met e 1 were converted into the
homologous sequence of fish tropomyosins.
The second hypoallergen MED171 was designed by deleting all
IgE-binding epitopes, which results in a smaller-sized truncated
tropomyosin variant of only 171 amino acid residues. With the
disruption of all epitopes and possibly its structural flexibility as in
tropomyosin, IgE reactivity and allergenicity of MED171 should
be more significantly abolished. From our data, both variant
showed significant reduction in their in vitro reactivity towards
Met e 1-specific IgE from patients and sensitized mice. Both of
them also lost their in vivo allergenicity in inducing mast cell
degranulation or IgE synthesis. Direct ELISA also demonstrated
that the IgE reactivity of MED171 is significantly lower than
MEM49 when tested with sera from Met e 1-sensitized mice (2.4%
IgE reactivity retained comparing to 9.5% in MEM49), which
matches with our initial expectation.
We noted that most of the human shrimp tropomyosin CD4+ T
cell epitopes mapped by Ravkov et al. [62] remain intact in both
hypoallergens and therefore, both MEM49 and MED171 should
retain their immunogenicity in inducing IgG antibodies. This is
supported by our data that a robust Met e 1-specific IgG response
was induced by MEM49 and MED171. Notably, we specifically
detected the production of IgG2a antibodies in mice immunized
with MEM49 or MED171, but not with the wild type allergen Met
e 1. The Th1-driven allergen-specific IgG2a antibody in mouse
and IgG4 antibody in human induced during SIT are considered
to be blocking antibodies and correlate well with clinical
improvements [63–71]. The fast-acting blocking IgG antibodies
provides protection possibly through the formation of IgG/
FccRIIb complex on mast cells that down-regulates IgE receptor
FceRI signaling and mast cell degranulation [70,72], sequestration
of the circulating allergen by the induced IgGs [73], and/or IgE
internalization facilitated by the formation of IgG/FccRIIb
immune complex [74]. In fact, our study provides evidence that
a MEM49- or MED171-based treatment may bring forth this
beneficial effect, because we found that both hypoallergens were
able to induce strong Met e 1-specific IgG2a responses even a pro-
Th2 adjuvant was used during immunization. Such production of
specific IgG2a and absence of Met e 1-specific IgE might
correspond to the Th1-driving potential of the two hypoallergens.
Most importantly, these antibodies were able to significantly block
IgE of both shrimp allergy subjects and Met e 1-sensitized mice
Figure 4. Immuno-reactivity of hypoallergens and inhibitory potential of the induced IgG antibodies. Reactivity of the rMet e 1-,
MEM49- and MED171-induced (A) IgG and (B) IgG2a antibodies towards the wild type allergen rMet e 1. Note that specific IgG2a could only be
induced by the hypoallergens. Inhibitory potential of the induced IgG towards Met e 1-specific IgE from (C) shrimp allergy subjects (n = 8) and (D)
Met e 1-sensitized mice (n = 8) determined by competitive inhibition ELISA. Percentage inhibition was calculated by [(ODno inhibitor–ODinhibitor)/ODno
inhibitor]6100%. Note that the MEM49- and MED171-induced IgG antibodies could significantly inhibit IgE of shrimp allergy patients and Met e 1-
sensitized mice from binding to Met e 1.
doi:10.1371/journal.pone.0111649.g004
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from binding to Met e 1. Such inhibitory and Th1-inducing
potential are beneficial and it is likely that a MEM49- or
MED171-based vaccine will modulate shrimp tropomyosin-
induced allergic responses.
To our knowledge, this is the first study providing experimental
evidence of a shellfish allergen-specific IgG blocking antibodies
induced by hypoallergens. Our results demonstrate significant
decrease in the in vivo and in vitro IgE reactivity and allergenicity
of the two designer shrimp tropomyosin hypoallergens MEM49
and MED171 when compared to the wild type allergen Met e 1
and more importantly, robust IgG antibodies’ responses with
inhibitory potential to Met e 1-specific IgE antibodies of shrimp
allergy subjects and Met e 1-sensitized mice. Finally, this work
signifies an important discovery that could potentiate the
development of prophylactic and/or therapeutic therapies in
shellfish allergy.
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Figure S1 Comparison of the tropomyosin sequences for the
construction of hypoallergen MEM49. Tropomyosin sequence of
Met e 1 was compared to that of four fish species Salmo salar
(Atlantic salmon), Epinephelus coioides (orange-spotted grouper),
Siniperca chuatsi (Mandarin fish) and Thunnus thynns (Atlantic
bluefin tuna). Amino acid deviations within each IgE-binding
epitope (framed) were identified and subsequently mutated into
the homologous sequence of fish tropomyosins (bold letters shaded
in gray) for the construction of hypoallergen MEM49.
(TIF)
Figure S2 Computational prediction of tropomyosin IgE-
binding epitopes. (A) Surface probability score of each amino
acid residue of Met e 1 in Emini Surface Accessbility Prediction.
(B) Antigenic propensity score of each amino acid residue of Met e
1 in Kolaskar & Tongaonkar Antigenicity. (C) Epitope score of
each amino acid residue of Met e 1 in Bepipred Linear Epitope
Prediction.
(TIF)
Table S1 Clinical characteristics and shrimp tropomyosin-
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12 patients 3–17 years old with documented history of shrimp
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binding epitopes of Met e 1 and characterizing the IgE reactivity
of the hypoallergens.
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